Zomedica reports record Q4 revenue $7.9M, full year $27.3M; net loss narrows to $7.2M

Zomedica Corp.

Q4 2024 revenue $7.9M (+8% YoY); full year $27.3M, also up 8% from 2023.
Gross margin 70.3% for Q4 and 70.0% for full year, at high end of 65-70% guidance.
Net loss improved to $7.2M in Q4 from $22.4M a year ago; full year net loss $47.0M vs $34.5M.
Diagnostics segment revenue surged 109% YoY in Q4 driven by TRUFORMA and VETGuardian adoption.
Cash, equivalents and securities $71.4M; adjusted non-GAAP EBITDA loss $20.2M for full year.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.